粉样蛋白前体蛋白的脑血管保护功能:进展和治疗前景
Zvonimir S Katusic1, Livius V d'Uscio1, Tongrong He1
1Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN 55902, USA; Department of Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55902, USA.
Pharmacology & therapeutics
|September 7, 2025
概括
粉样蛋白前体蛋白 (APP) 通过维持内皮功能来保护大脑血管. 失去APP会损害关键蛋白质,导致功能障碍和潜在的阿尔茨海默病.
科学领域:
- 神经科学是一个神经科学.
- 血管生物学 血管生物学
- 分子生物学分子生物学
背景情况:
- 粉样蛋白前体蛋白 (APP) 对于大脑发育和功能至关重要.
- 在APP的dyshomeostasis有助于阿尔茨海默病和大脑粉样血管病变.
- 内皮细胞APP在维持脑血管健康方面发挥着至关重要的作用.
研究的目的:
- 审查关于大脑内皮细胞APP血管保护功能的文献.
- 检查APP在内皮功能障碍中的作用及其与神经退行性疾病的联系.
- 探索针对APP的治疗干预的转化机会.
主要方法:
- 审查现有的科学文献.
- 使用培养人类大脑微血管内皮的研究分析.
- 检查基因改造的APP缺乏症小鼠模型的数据.
主要成果:
- 失去APP会损害克鲁佩尔样因子2 (KLF2) 和内皮氧化合成酶 (eNOS) 的表达和功能.
- 在人类和小鼠脑血管内皮中,APP缺乏导致内皮功能障碍.
- APP表现出血管保护作用,特别是在衰老期间.
结论:
- 内皮细胞APP是大脑中关键的血管保护蛋白.
- 了解APP的大脑血管功能为神经退行性疾病提供了治疗潜力.
- 药理上活跃的APP域可以作为新疗法的模板.
相关概念视频
Amyloid Fibrils
11.7K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.7K
Amyloid Fibrils
6.3K
6.3K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827
The Blood-brain Barrier
52.4K
Overview
52.4K


